Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gastrointestinal tumours, colorectal 2

3688 - Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): post hoc analysis of the MOSAIC trial.

Date

21 Oct 2018

Session

Poster Discussion session - Gastrointestinal tumours, colorectal 2

Topics

Cytotoxic Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Edouard Auclin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

E. Auclin1, T. Andre2, J. Taieb3, M. Banzi4, J. van Laethem5, J. Tabernero6, T. Hickish7, A. De Gramont8, D. Vernerey9

Author affiliations

  • 1 Oncology, Hopital Européen George Pompidou, 75015 - Paris/FR
  • 2 Service D'oncologie Médicale, Sorbonne Université et Hôpital Saint-Antoine, 75 - Paris/FR
  • 3 Department Of Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 4 Oncology, arcispedale santa maria nuova-IRCCS, reggio emilia/IT
  • 5 Oncology, Erasme University Hospital-(Universite Libre de Bruxelles), 1070 - Brussels/BE
  • 6 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 7 Oncology, Royal Bournemouth Hospital and University, Bournemouth/GB
  • 8 Medical Oncology, Institut hospitalier Franco-Britannique, 92300 - Levallois Perret/FR
  • 9 Statistics, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
More

Resources

Abstract 3688

Background

Adjuvant chemotherapy (LV5FU2 +/- oxaliplatin) is recommended for high risk (T4 and/or bowel perforation and/or number of nodes examined <10) stage II CC. After curative treatment (ttt), CEA measurement is recommended for follow up. CEA above 5 ng/mL is of poor prognosis, however recently a cut-off of 2.35 was shown to be more appropriate, in a cohort of 40,000 patients (pts). We explored the postoperative CEA prognostic value and its predictive value for the benefit of oxaliplatin addition to LV5FU2 adjuvant chemotherapy.

Methods

Stage II CC pts in MOSAIC study with postoperative CEA available were included. Overall (OS) and Disease Free Survival (DFS) were estimated with the Kaplan Meier method. CEA predictive value for benefit of oxaliplatin addition to LV5FU2 on survival was evaluated with an interaction term between treatment and CEA risk group in the Cox model, firstly in the whole stage II population, then according to high/low risk groups.

Results

CEA was available in 867 pts (96.4%), with n = 664 ≤ 2.35 (group 1) and n = 203 > 2.35 (group 2). 3y OS rates were 96%, and 90% in groups 1 and 2, p = 0.02. 3y DFS rates were 88%, and 79%, p = 0.006. There was an interaction between CEA level and ttt arm (LV5FU2 or FOLFOX) for OS (interaction term p = 0.03) and DFS (p = 0.11), Table. This was confirmed in high risk (interaction term p = 0.03 and 0.09, for OS and DFS) but not in low risk stage II CC (p = 1 and 0.78 for OS and DFS), Table. CEA was associated with an improvement of oxaliplatin benefit in OS and DFS in high risk stage II CC pts.Table: 462PD

3y OS and DFS in the MOSAIC stage II pts according to postoperative CEA level and ttt arm

3y OS %3y DFS %
LV5FU2FOLFOXLV5FU2FOLFOX
Whole populationCEA ≤2.35 ng/mL97.393.988.288.7
>2.3588.492.576.081.1
Low riskCEA ≤2.35ng/mL98.895.791.891.5
>2.3590.391.478.675.8
High riskCEA ≤2.35 ng/mL95.592.584.086.3
>2.3587.093.674.087.2

Conclusions

We validated that postoperative CEA with a CEA cut-off of 2.35 ng/mL was prognostic for OS and DFS in stage II CC. CEA was also predictive of oxaliplatin benefit in OS and DFS for high risk stage II CC. External validation on the CEA predictive value is ongoing and will be presented with this cohort.

Clinical trial identification

Legal entity responsible for the study

Dewi Vernerey.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

T. Andre: Honoraria: Roche/Genentech, Bristol-Myers Squibb, Servier, xBiotech, Bayer Sanofi, Amgen, PRMA Consulting; Advisory role: Roche/Genentech, Amgen, Bristol-Myers Squibb, Mundipharma International, HalioDX, MSD Oncology, Servier, Guardant Health, Bayer. J. Taieb: Advisory role: Roche, Merck KGaA, Amgen, Lilly, Baxalta, Servier and Sirtex Medical. J. Tabernero: Advisory role: Bayer, Boehringer Ingelheim, Lilly, MSD, Merck Serono, Novartis, Roche, Sanofi, Taiho Pharmaceutical, Genentech/Roche, Merrimack, Symphonu Evolution, Peptomyc. T. Hickish: Research funding: xBiotech, Roche, Pfizer, Novartis, Merck. A. de Gramont: A. Honoraria: Yakult, Chugai Pharma. D. Vernerey: Advisory role: OSE Immunotherapeutics, Janssen-Cilag, Prestizia, HalioDX. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.